Open-label RCT in 60 children with class III/IV lupus nephritis: adding belimumab to standard therapy was associated with expanded IL-10-producing regulatory B cells, fewer ILC1s, lower proteinuria and better SLEDAI-2K scores than standard therapy alone.
RCTn = 60
Lin et al. Regulatory B cell expansion and type 1 innate lymphoid cell suppression characterise immune modulation in paediatric lupus nephritis